259 related articles for article (PubMed ID: 12124569)
1. Trimodality treatment versus surgery alone for esophageal cancer. A stratified analysis with minimally invasive pretreatment staging.
Jiao X; Sonett J; Gamliel Z; Doyle A; Schuetz J; Greenwald B; Suntharalingam M; Krasna MJ
J Cardiovasc Surg (Torino); 2002 Aug; 43(4):531-7. PubMed ID: 12124569
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment surgical lymph node staging predicts results of trimodality therapy in esophageal cancer.
Jiao X; Krasna MJ; Sonett J; Gamliel Z; Suntharalingam M; Doyle A; Greenwald B
Eur J Cardiothorac Surg; 2001 Jun; 19(6):880-6. PubMed ID: 11404146
[TBL] [Abstract][Full Text] [Related]
3. Accurate lymph node assessment prior to trimodality therapy for esophageal carcinoma.
Suntharalingam M; Haas ML; Sonett JR; Doyle LA; Hausner PF; Schuetz J; Greenwald B; Krasna MJ
Cancer J; 2001; 7(6):509-15. PubMed ID: 11769864
[TBL] [Abstract][Full Text] [Related]
4. Treatment of maxillary sinus carcinoma: a comparison of the 1997 and 1977 American Joint Committee on cancer staging systems.
Le QT; Fu KK; Kaplan M; Terris DJ; Fee WE; Goffinet DR
Cancer; 1999 Nov; 86(9):1700-11. PubMed ID: 10547542
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.
Chao YK; Chan SC; Liu YH; Chen HW; Wan YL; Chang HK; Fan KH; Liu HP
Ann Surg; 2009 Mar; 249(3):392-6. PubMed ID: 19247024
[TBL] [Abstract][Full Text] [Related]
6. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
[TBL] [Abstract][Full Text] [Related]
7. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
[TBL] [Abstract][Full Text] [Related]
8. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience.
Blum Murphy M; Xiao L; Patel VR; Maru DM; Correa AM; G Amlashi F; Liao Z; Komaki R; Lin SH; Skinner HD; Vaporciyan A; Walsh GL; Swisher SG; Sepesi B; Lee JH; Bhutani MS; Weston B; Hofstetter WL; Ajani JA
Cancer; 2017 Nov; 123(21):4106-4113. PubMed ID: 28885712
[TBL] [Abstract][Full Text] [Related]
9. Is pathological complete response after a trimodality therapy, a predictive factor of long-term survival in locally-advanced esophageal cancer? Results of a retrospective monocentric study.
Francoual J; Lebreton G; Bazille C; Galais MP; Dupont B; Alves A; Lubrano J; Morello R; Menahem B
J Visc Surg; 2018 Oct; 155(5):365-374. PubMed ID: 29501383
[TBL] [Abstract][Full Text] [Related]
10. Primary Gross Tumor Volume is an Important Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Trimodality Therapy.
Boggs DH; Hanna A; Burrows W; Horiba N; Suntharalingam M
J Gastrointest Cancer; 2015 Jun; 46(2):131-7. PubMed ID: 25759174
[TBL] [Abstract][Full Text] [Related]
11. Baseline nutritional status is prognostic factor after definitive radiochemotherapy for esophageal cancer.
Clavier JB; Antoni D; Atlani D; Ben Abdelghani M; Schumacher C; Dufour P; Kurtz JE; Noel G
Dis Esophagus; 2014 Aug; 27(6):560-7. PubMed ID: 23106980
[TBL] [Abstract][Full Text] [Related]
12. Multimodal treatment strategy for clinical T3 thoracic esophageal cancer.
Saeki H; Morita M; Tsuda Y; Hidaka G; Kasagi Y; Kawano H; Otsu H; Ando K; Kimura Y; Oki E; Kusumoto T; Maehara Y
Ann Surg Oncol; 2013 Dec; 20(13):4267-73. PubMed ID: 23943036
[TBL] [Abstract][Full Text] [Related]
13. [The multimodality therapy of advanced inoperable esophageal carcinoma. A retrospective analysis].
Mücke R; Ziegler PG; Libera T; Klautke G; Fietkau R
Strahlenther Onkol; 2000 Aug; 176(8):350-5. PubMed ID: 10987017
[TBL] [Abstract][Full Text] [Related]
14. Resectable esophageal carcinoma: local control with neoadjuvant chemotherapy and radiation therapy.
Chidel MA; Rice TW; Adelstein DJ; Kupelian PA; Suh JH; Becker M
Radiology; 1999 Oct; 213(1):67-72. PubMed ID: 10540642
[TBL] [Abstract][Full Text] [Related]
15. Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy.
Kim MK; Cho KJ; Park SI; Kim YH; Kim JH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Song HJ; Ryu JS; Kim SB
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):115-21. PubMed ID: 19251379
[TBL] [Abstract][Full Text] [Related]
16. Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study.
Mantziari S; Gronnier C; Renaud F; Duhamel A; Théreaux J; Brigand C; Carrère N; Lefevre JH; Pasquer A; Demartines N; Collet D; Meunier B; Mariette C;
Ann Surg; 2017 Nov; 266(5):805-813. PubMed ID: 28742698
[TBL] [Abstract][Full Text] [Related]
17. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
[TBL] [Abstract][Full Text] [Related]
18. Is combined chemotherapy and radiation therapy equally effective as surgical resection in localized esophageal carcinoma?
Chan A; Wong A
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):265-70. PubMed ID: 10487544
[TBL] [Abstract][Full Text] [Related]
19. Treatment of clinical T2N0M0 esophageal cancer.
Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
[TBL] [Abstract][Full Text] [Related]
20. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
